TY - JOUR
T1 - Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti–PD-1 Therapy
AU - Inozume, Takashi
AU - Yaguchi, Tomonori
AU - Ariyasu, Ryo
AU - Togashi, Yosuke
AU - Ohnuma, Takehiro
AU - Honobe, Akiko
AU - Nishikawa, Hiroyoshi
AU - Kawakami, Yutaka
AU - Kawamura, Tatsuyoshi
N1 - Funding Information:
This work was supported by JSPS KAKENHI Grant Number 16K10148 .
Publisher Copyright:
© 2019 The Authors
PY - 2019/7
Y1 - 2019/7
N2 - Major histocompatibility complex class I loss due to the abnormality of β2-microglobulin gene is one of the mechanisms underlying delayed relapses in melanoma patients long after the initial positive responses to anti–PD-1 therapy. However, the tumor-specific reactivity of tumor-infiltrating lymphocytes in tumor lesions that lost major histocompatibility complex class I expression has not been well evaluated. We report the case of a 55-year-old woman with two metastatic melanoma lesions. After a 12-month period of successful tumor suppression by anti–PD-1 antibody therapy, one lesion started to grow again. We resected both lesions and examined the tumor cells and tumor-infiltrating lymphocytes. The shrinking lesion consisted of necrotic tissue and macrophages, and the enlarged lesion consisted of both necrotic tissue and viable tumor cells. The tumor cells completely lost major histocompatibility complex class I expression, but it was restored upon retroviral transduction of the normal β2-microglobulin gene. When we checked the tumor-specific reactivity of tumor-infiltrating lymphocytes derived from the relapsing lesion, we found that these tumor-infiltrating lymphocytes failed to recognize the native tumor cells derived from the lesion, but strongly recognized the major histocompatibility complex class-I–recovered cells by β2-microglobulin transduction. Our report emphasizes the limitations of T-cell–based immunotherapy and highlights the importance of developing alternative strategies for such cases.
AB - Major histocompatibility complex class I loss due to the abnormality of β2-microglobulin gene is one of the mechanisms underlying delayed relapses in melanoma patients long after the initial positive responses to anti–PD-1 therapy. However, the tumor-specific reactivity of tumor-infiltrating lymphocytes in tumor lesions that lost major histocompatibility complex class I expression has not been well evaluated. We report the case of a 55-year-old woman with two metastatic melanoma lesions. After a 12-month period of successful tumor suppression by anti–PD-1 antibody therapy, one lesion started to grow again. We resected both lesions and examined the tumor cells and tumor-infiltrating lymphocytes. The shrinking lesion consisted of necrotic tissue and macrophages, and the enlarged lesion consisted of both necrotic tissue and viable tumor cells. The tumor cells completely lost major histocompatibility complex class I expression, but it was restored upon retroviral transduction of the normal β2-microglobulin gene. When we checked the tumor-specific reactivity of tumor-infiltrating lymphocytes derived from the relapsing lesion, we found that these tumor-infiltrating lymphocytes failed to recognize the native tumor cells derived from the lesion, but strongly recognized the major histocompatibility complex class-I–recovered cells by β2-microglobulin transduction. Our report emphasizes the limitations of T-cell–based immunotherapy and highlights the importance of developing alternative strategies for such cases.
UR - http://www.scopus.com/inward/record.url?scp=85062660151&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062660151&partnerID=8YFLogxK
U2 - 10.1016/j.jid.2019.01.007
DO - 10.1016/j.jid.2019.01.007
M3 - Article
C2 - 30684558
AN - SCOPUS:85062660151
SN - 0022-202X
VL - 139
SP - 1490
EP - 1496
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 7
ER -